DMK
ALNY icon

David M. Knott’s Alnylam Pharmaceuticals ALNY Stock Holding History

David M. Knott’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-500
Closed -$47K – 113
2019
Q1 		$47K Hold
500
– – 0.02% 96
2018
Q4 		$36K Hold
500
– – 0.02% 89
2018
Q3 		$44K Hold
500
– – 0.01% 94
2018
Q2 		$49K Buy
500
+251
+101% +$24.9K 0.02% 98
2018
Q1 		$30K Hold
249
– – 0.01% 96
2017
Q4 		$32K Buy
249
+139
+126% +$17.5K 0.01% 98
2017
Q3 		$13K Buy
+110
New +$9.39K 0.01% 104

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

David M. Knott's ALNY Position: Q2 2019 in Review

David M. Knott sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2019, closing a stake of 500 shares — an estimated $47K sold.

David M. Knott first reported a position in ALNY in Q3 2017 and held it in 7 quarters. The position peaked at $49K in Q2 2018. 290 funds tracked by Wall St. Rank hold ALNY as of Q2 2019.

  • David M. Knott reported no remaining Alnylam Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • David M. Knott sold 500 Alnylam Pharmaceuticals shares in Q2 2019, an estimated $47K.
  • David M. Knott first reported a position in Alnylam Pharmaceuticals in Q3 2017 and held it in 7 quarters.
  • David M. Knott's Alnylam Pharmaceuticals position peaked at $49K in Q2 2018.
  • 290 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2019.

Based on David M. Knott's 13F filing for Q2 2019, filed 12 Aug 2019.